Perspective Therapeutics (NYSEAMERICAN:CATX) Now Covered by Jonestrading

Stock analysts at Jonestrading started coverage on shares of Perspective Therapeutics (NYSEAMERICAN:CATX) in a research report issued on Wednesday, Benzinga reports. The brokerage set a “buy” rating and a $1.40 price target on the stock.

Perspective Therapeutics Stock Up 2.8 %

NYSEAMERICAN:CATX opened at 0.26 on Wednesday. Perspective Therapeutics has a 12 month low of 0.21 and a 12 month high of 0.73. The company has a current ratio of 3.72, a quick ratio of 3.59 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $72.61 million, a P/E ratio of -2.88 and a beta of 1.70.

Hedge Funds Weigh In On Perspective Therapeutics

Several hedge funds have recently made changes to their positions in CATX. Creative Planning bought a new position in shares of Perspective Therapeutics in the third quarter valued at approximately $35,000. HighTower Advisors LLC purchased a new stake in Perspective Therapeutics in the 3rd quarter worth approximately $314,000. Charles Schwab Investment Management Inc. bought a new position in Perspective Therapeutics in the 3rd quarter valued at $32,000. Perkins Capital Management Inc. purchased a new position in shares of Perspective Therapeutics during the 3rd quarter valued at $731,000. Finally, Bank of New York Mellon Corp bought a new position in shares of Perspective Therapeutics in the third quarter worth $42,000. 23.20% of the stock is currently owned by hedge funds and other institutional investors.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers.